Luxembourg

Additional Risk minimisation materials to minimise potential risk associated with the use of medicines. The materials have been assessed and approved by the national competent authority in line with their Marketing Authorisation requirements.

Flixabi (Infliximab)
Imraldi (Adalimumab)